(Q34549725)

English

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

scientific article

Statements

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle (English)
Roswitha Forstpointner
Roland Repp
Sandra Hermann
Annette Hänel
Bernd Metzner
Frank Hartmann
Frank Rothmann
Robert Rohrberg
Hans-Peter Böck
German Low-Grade Lymphoma Study Group
3064-3071

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit